Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

S. Ying; Jia Wang; C. Xu; Y. Kang; X. Zhang; L. Shi; L. Fan; Z. Wang; J. Zhou; X. Wu; J. Wu; W. Li; G. Liang

doi:10.1134/S1070363216120355

Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

Authors: Ying S.¹, Wang J.¹, Xu C.¹, Kang Y.¹, Zhang X.¹, Shi L.¹, Fan L.¹, Wang Z.¹, Zhou J.¹, Wu X.¹, Wu J.¹, Li W.¹^,2, Liang G.¹
Affiliations:
1. Chemical Biology Research Center, College of Pharmaceutical Sciences
2. College of Information Science and Computer Engineering
Issue: Vol 86, No 12 (2016)
Pages: 2744-2751
Section: Article
URL: https://journals.rcsi.science/1070-3632/article/view/216870
DOI: https://doi.org/10.1134/S1070363216120355
ID: 216870

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Fibroblast growth factor receptor 1 (FGFR1) is considered a therapeutic target for multiple cancers, including gastric cancer. FGFR1 inhibitors, being ATP competitors, can prevent the kinase domain and the downstream signaling cascade from phosphorylation and thus have the potential to treat cancers associated with aberrant FGFR1 activation. However, untargeted inhibition may cause numerous side effects. Thus, a non-ATP competitive FGFR1 inhibitor should be urgently identified and explored. In this study, we designed and synthesized 17 derivatives of nordihydroguaiaretic acid (NDGA), a known ATP-independent FGFR3 inhibitor. In the kinase activity assay, 3,5-bis(2-fluorobenzylidene)piperidin-4-one (1B) showed the highest kinase inhibitory activity among all derivatives and was thus identified as a non-ATP-competitive FGFR1 inhibitor. In the biological effect evaluation, 1B restrained the FGFR−FRS2−ERK signaling pathway in a dose-dependent manner and inhibited the growth of two gastric cancer cell lines. Overall, 1B can be considered as a potential candidate for treating gastric cancer and as an outstanding lead compound for the discovery of novel non-ATPcompetitive FGFR1 inhibitors.

Keywords

antitumor activity, design and synthesis, FGFR1 inhibitors, gastric cancer, NDGA analogs, non-ATP-competitive protein kinase inhibitor

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Design, synthesis, and antiproliferative activity assessment of non-ATP-competitive fibroblast growth factor receptor 1 inhibitors

Full Text

Abstract

Keywords

About the authors

This website uses cookies